TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05825001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive active EFT stimulus

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (control)
Description: Receive control EFT stimulus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use iCOquit Smokerlyzer carbon monoxide monitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use iCOquit Smokerlyzer carbon monoxide monitor
Study: NCT05454566

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ICM-203
Description: Intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ICM-203
Description: Intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ICM-203
Description: Intra-articular injection
Study: NCT05518162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InBloom
Description: The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ROSE
Description: ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions.
Study: NCT05207943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
Study: NCT06370351

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SENS-501 administration
Description: Administration of SENS-501 with a dedicated administration system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SENS-501 administration
Description: Administration of SENS-501 with a dedicated administration system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SENS-501 administration
Description: Administration of SENS-501 with a dedicated administration system
Study: NCT06546696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Competency Based Approaches to Community Health (COACH)
Description: COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competency Based Approaches to Community Health (COACH)
Description: COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
Study: NCT05008224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study: NCT05384457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity training
Description: Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity training
Description: Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
Study: NCT05207943

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
Study: NCT05008224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study: NCT05142319

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous mRNA booster vaccine
Description: Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous mRNA booster vaccine
Description: Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN
Description: Single intradermal injection at 6ug (0.5ml) per dose.
Study: NCT05075057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: three doses of inactivated COVID-19 vaccine
Study: NCT05142319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nuvaxovid
Description: Single intradermal injection at 5mcg (0.5mL) per dose.
Study: NCT06291701

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of scapular endurance
Description: For the assessment of scapular endurance, participants will be instructed to bend their arms and elbows while keeping a wooden rod placed between their elbows, pull a spring dynamometer placed between thei

Intervention type: DIAGNOSTIC_TEST
Intervention: Prone Bridge Test
Description: For the Prone Bridge Test, participants will be instructed to lie face down with their hands and feet shoulder-width apart and then raise their bodies off the ground by lifting themselves up on their hands, forearms, and toes. A stopwa

Intervention type: DIAGNOSTIC_TEST
Intervention: Side Bridge Test
Description: For the Side Bridge Test, participants will be asked to lie on their right side, supporting themselves on their forearm and elbow, and lift themselves off the ground. A stopwatch will be started, and the test will be terminated if there is any deviation from the position. The elapsed time will be recorded in seconds. The test will then be repeated on the left side.

Intervention type: DIAGNOSTIC_TEST
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: For the Closed Kinetic Chain Upper Extremity Stability Test, participants will be asked to assume a push-up position on a flat surface with their hands placed on two parallel lines drawn 90 cm apart. They will then be instructed to touch one hand to the other hand's side as many times as possible within 15 seconds. The test will be repeated three times, and the average of the scores will be calculated.
Study: NCT05862584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Distribution of questionnaires to patients to be completed on a weekly basis.
Study: NCT04838197

Intervention type: OTHER
Intervention: Questionnaires and Surveys
Description: Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
Study: NCT05736406

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2
Description: 5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Description: 5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
Study: NCT05871996

Intervention type: OTHER
Intervention: Palliative Care and Oncology Survey on Terminology (POST)
Description: Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.

Intervention type: OTHER
Intervention: Palliative Care and Oncology Survey on Terminology (POST)
Description: Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
Study: NCT04957355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)
Description: Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)
Study: NCT06274567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham (placebo) TMS
Description: Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
Study: NCT05584137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Study: NCT04811573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product
Study: NCT05679622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
Study: NCT04811573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2
Study: NCT06291701

Intervention type: DIAGNOSTIC_TEST
Intervention: Seated Medicine Ball Throw Test
Description: For the Seated Medicine Ball Throw Test, participants will be asked to sit on the ground with their back, shoulders, and head against the wall. Holding a 2 kg medicine ball with both hands, they will start with their elbows bent and arms at their sides, then extend their elbows to throw the ball forward as far as possible. The distance between the wall and the point where the ball lands will be recorded. The test will be performed three times, and the average will be calculated.
Study: NCT05063331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)
Description: Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
Description: The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
Study: NCT05172999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel-releasing intrauterine system
Description: Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing intrauterine system
Description: Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Loxenatide
Description: Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
Study: NCT06336434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA 600mg
Description: 600mg (3mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA 600mg
Description: 600mg (3mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA 600mg
Description: 600mg (3mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA 900mg
Description: 900mg (3mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA 900mg
Description: 900mg (3mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA 900mg
Description: 900mg (3mL) IM Injection
Study: NCT04811573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2
Study: NCT06336434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA 400mg
Description: 400mg (2mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA 400mg
Description: 400mg (2mL) IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA 600mg
Description: 600mg (2mL) IM injection
Study: NCT04811573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2